Novo Nordisk logs DKK 8.7B in share buybacks

Rhea-AI Filing Summary

Novo Nordisk A/S (NVO) reports progress on its ongoing share repurchase programme conducted under EU Safe Harbour Rules. The company plans to repurchase B shares for up to DKK 15 billion during a 12‑month period beginning 4 February 2026, as part of its capital allocation strategy.

Under the sub-programme initiated on 6 May 2026, Novo Nordisk may buy back B shares for up to DKK 11,200,000,010.45 through 1 February 2027. As of 28 August 2026, it has repurchased 30,979,179 B shares at an average price of DKK 281.08, for a total of DKK 8,707,673,805. Novo Nordisk now holds 45,019,876 B shares as treasury shares, equal to 1.0% of its 4,465,000,000 total A and B shares.

Filing Explained

The report adds five completed B-share purchases from August 24, 2026 through August 28, 2026; accumulated under this sub-programme, purchases total 16,220,000 shares for DKK 4,907,673,815.

Key Figures

Overall share repurchase programme size: DKK 15,000,000,000 Sub-programme cap: DKK 11,200,000,010.45 Shares repurchased since 4 February 2026: 30,979,179 B shares +5 more

8 metrics

Overall share repurchase programme size DKK 15,000,000,000 Expected B share repurchases during 12-month period beginning 4 February 2026

Sub-programme cap DKK 11,200,000,010.45 Maximum B share repurchases from 6 May 2026 to 1 February 2027

Shares repurchased since 4 February 2026 30,979,179 B shares Total B shares repurchased as of 28 August 2026

Average repurchase price DKK 281.08 per B share Average price for 30,979,179 B shares repurchased since 4 February 2026

Total repurchase value DKK 8,707,673,805 Transaction value of B share repurchases since 4 February 2026

Treasury B shares 45,019,876 B shares B shares held as treasury shares, equal to 1.0% of share capital

Total share capital 4,465,000,000 A and B shares Total number of A and B shares, including treasury shares

Employees 68,800 Number of employees globally

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, American Depositary Receipts, +1 more

5 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"Novo Nordisk owns a total of 45,019,876 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"in accordance with ... (the "Safe Harbour Rules")"

American Depositary Receipts financial

"Its ADRs are listed on the New York Stock Exchange (NVO)"

A certificate traded on U.S. markets that represents ownership of shares in a foreign company, letting U.S. investors buy and sell that company as if it were listed domestically. Think of it as a local voucher for a foreign product: it makes price quotes in dollars, trades on familiar exchanges, and brings differences in liquidity, fees and legal protections that can affect returns and risk compared with buying the underlying foreign shares directly.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

What is the size of Novo Nordisk (NVO)'s current share repurchase programme?

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12‑month period beginning 4 February 2026. This programme includes a sub-programme initiated on 6 May 2026 under EU Safe Harbour Rules.

How much has Novo Nordisk (NVO) repurchased under the programme so far?

As of 28 August 2026, Novo Nordisk has repurchased a total of 30,979,179 B shares at an average price of DKK 281.08 per B share, corresponding to a total transaction value of DKK 8,707,673,805 since 4 February 2026.

What are the details of Novo Nordisk (NVO)'s May 2026 sub-programme?

Under the sub-programme initiated on 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027, conducted in accordance with EU Safe Harbour Rules.

How many treasury shares does Novo Nordisk (NVO) currently hold?

Following the reported transactions, Novo Nordisk owns 45,019,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of its share capital. Total A and B shares in the company amount to 4,465,000,000, including treasury shares.

On which exchanges are Novo Nordisk (NVO) securities listed?

Novo Nordisk’s B shares are listed on Nasdaq Copenhagen under the symbol Novo-B, and its ADRs are listed on the New York Stock Exchange under the symbol NVO.

How large is Novo Nordisk’s (NVO) global workforce and footprint?

Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries, reflecting its position as a leading global healthcare company headquartered in Denmark.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 09:12 AM Accepted by SEC EDGAR 08/31/2026 - 09:11 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

August 31, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 31 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 24 August, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	15,170,000		4,590,476,842
24 August 2026	210,000	301.87	63,393,359
25 August 2026	210,000	306.00	64,259,374
26 August 2026	210,000	308.60	64,805,405
27 August 2026	210,000	296.89	62,346,025
28 August 2026	210,000	297.11	62,392,810
Accumulated under the programme	16,220,000		4,907,673,815

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 45,019,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 28 August 2026, Novo Nordisk has since 4 February 2026 repurchased a total 30,979,179 B shares at an average share price of DKK 281.08 per B share equal to a transaction value of DKK 8,707,673,805.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown	Liz Skrbkova (US)
+45 3079 9289	+1 609 917 0632
globalmedia@novonordisk.com	USMediaRelations@novonordisk.com
Investors:
Michael Novod	Sina Meyer
+45 3075 6050	+45 3079 6656
nvno@novonordisk.com	azey@novonordisk.com
Alex Bruce	Ida Schaap Melvold
+45 3444 2613	+45 3077 5649
axeu@novonordisk.com	idmg@novonordisk.com
Christoffer Togo Solgaard-Tullin	Mads Berner Bruun
+45 3079 1471	+45 3075 2936
cftu@novonordisk.com	mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 53 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: August 31, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer